European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | The Lancet Neurology |
Vol/bind | 23 |
Udgave nummer | 3 |
Sider (fra-til) | 302-312 |
Antal sider | 11 |
ISSN | 1474-4422 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.
Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.
Publisher Copyright:
© 2024 Elsevier Ltd
ID: 384254871